BPMC - Blueprint Medicines Corp

QQQ $ 437.97 $ -13.38 (-2.98 %)

DIA $ 386.91 $ -10.32 (-2.6 %)

SPY $ 518.58 $ -15.52 (-2.91 %)

TLT $ 98.76 $ 0.52 (0.53 %)

GLD $ 222.59 $ -2.86 (-1.27 %)

Previous Close

$ 92.97

Open

Bid

$ 92.95 x 100

Ask

$ 92.92 x 100

Day's Range

-- - --

52 Week Range

$ 43.89 - $ 121.90

Volume

1,549,683

Average Volume

Market Cap

5.84B

Beta (5Y Monthly)

$ 1.05

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-01-2024	06-30-2024	10-Q
2	05-02-2024	03-31-2024	10-Q
3	02-15-2024	12-31-2023	10-K
4	10-26-2023	09-30-2023	10-Q
5	08-02-2023	06-30-2023	10-Q
6	05-04-2023	03-31-2023	10-Q
7	02-16-2023	12-31-2022	10-K
8	11-01-2022	09-30-2022	10-Q
9	08-02-2022	06-30-2022	10-Q
10	05-03-2022	03-31-2022	10-Q
11	02-17-2022	12-31-2021	10-K
12	10-28-2021	09-30-2021	10-Q
13	07-29-2021	06-30-2021	10-Q
14	04-29-2021	03-31-2021	10-Q
15	02-17-2021	12-31-2020	10-K
16	10-29-2020	09-30-2020	10-Q
17	07-31-2020	06-30-2020	10-Q
18	05-06-2020	03-31-2020	10-Q
19	02-13-2020	12-31-2019	10-K
20	11-05-2019	09-30-2019	10-Q
21	08-01-2019	06-30-2019	10-Q
22	05-09-2019	03-31-2019	10-Q
23	02-26-2019	12-31-2018	10-K
24	10-30-2018	09-30-2018	10-Q
25	08-01-2018	06-30-2018	10-Q
26	05-02-2018	03-31-2018	10-Q
27	02-21-2018	12-31-2017	10-K
28	10-31-2017	09-30-2017	10-Q
29	08-02-2017	06-30-2017	10-Q
30	05-03-2017	03-31-2017	10-Q
31	03-09-2017	12-31-2016	10-K
32	11-10-2016	09-30-2016	10-Q
33	08-09-2016	06-30-2016	10-Q
34	05-10-2016	03-31-2016	10-Q
35	03-11-2016	12-31-2015	10-K
36	11-09-2015	09-30-2015	10-Q
37	08-10-2015	06-30-2015	10-Q
38	06-11-2015	03-31-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Needham Maintains Buy on Blueprint Medicin...
08/05/2024 19:13:02

Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $130 to $133.

Guggenheim Maintains Buy on Blueprint Medi...
08/02/2024 19:10:14

Guggenheim analyst Michael Schmitz maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $...

Baird Maintains Outperform on Blueprint Me...
08/02/2024 14:44:21

Baird analyst Joel Beatty maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and raises the price target from $11...

Needham Reiterates Buy on Blueprint Medici...
08/01/2024 12:45:08

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $130 price target.

Blueprint Medicines Continues To Expect Th...
08/01/2024 11:11:19

Blueprint Medicines Corp Raised 2024 Globa...
08/01/2024 11:10:40

Blueprint Medicines Q2 2024 GAAP EPS $(0.8...
08/01/2024 11:09:08

Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $...

10-health-care-stocks-whale-activity-in-todays-session

10 Health Care Stocks Whale Activity In To...
07/30/2024 17:35:22

15 Analysts Have This To Say About Bluepri...
07/29/2024 19:00:55

Barclays Maintains Equal-Weight on Bluepri...
07/29/2024 15:45:12

Barclays analyst Peter Lawson maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price target fr...

Morgan Stanley Maintains Equal-Weight on B...
07/12/2024 17:18:03

Morgan Stanley analyst Michael Ulz maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price targ...

Oppenheimer Maintains Outperform on Bluepr...
07/08/2024 12:50:55

Oppenheimer analyst Matthew Biegler maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and raises the price targe...

Expert Ratings For Blueprint Medicines
06/28/2024 13:00:26

Needham Reiterates Buy on Blueprint Medici...
06/28/2024 10:15:02

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $130 price target.

Assessing Blueprint Medicines: Insights Fr...
06/07/2024 18:01:18

JMP Securities Reiterates Market Outperfor...
06/07/2024 17:14:38

JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and maintains $12...

10 Health Care Stocks Whale Activity In To...
05/17/2024 17:35:23

Unveiling 18 Analyst Insights On Blueprint...
05/14/2024 16:00:38

Stephens & Co. Initiates Coverage On Bluep...
05/14/2024 09:58:30

Stephens & Co. analyst Sudan Loganathan initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Overweight rating...

Leerink Partners Upgrades Blueprint Medici...
05/06/2024 17:47:46

Leerink Partners analyst Andrew Berens upgrades Blueprint Medicines (NASDAQ:BPMC) from Underperform to Market Perform and ra...